Pain News and Research

Latest Pain News and Research

Xgeva receives FDA approval for treating giant cell tumor of the bone

Xgeva receives FDA approval for treating giant cell tumor of the bone

NACC recommendations address established pain therapies and preview potential future advances

NACC recommendations address established pain therapies and preview potential future advances

Researchers create guidelines to reduce staph infections after surgery

Researchers create guidelines to reduce staph infections after surgery

AMPLE trial demonstrates similar safety profiles and efficacy between abatacept and adalimumab in RA

AMPLE trial demonstrates similar safety profiles and efficacy between abatacept and adalimumab in RA

Ustekinumab doses improve signs and symptoms of PsA with favourable safety profiles

Ustekinumab doses improve signs and symptoms of PsA with favourable safety profiles

Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

Study demonstrates efficacy of ARASHI method at evaluating radiographic joint damage in RA

Study demonstrates efficacy of ARASHI method at evaluating radiographic joint damage in RA

Study reveals 83% of teens have unsupervised access to prescription medications

Study reveals 83% of teens have unsupervised access to prescription medications

Using Swiss ball improves walking performance and muscle strength in AS patients

Using Swiss ball improves walking performance and muscle strength in AS patients

Society of Interventional Radiology releases Updates in Interventional Radiology 2013

Society of Interventional Radiology releases Updates in Interventional Radiology 2013

Constella® (linaclotide), for the symptomatic treatment of Irritable Bowel Syndrome with Constipation (IBS-C), is now available in Germany, UK and Nordic countries

Constella® (linaclotide), for the symptomatic treatment of Irritable Bowel Syndrome with Constipation (IBS-C), is now available in Germany, UK and Nordic countries

One-third of RA patients discontinue therapy within the first year of treatment

One-third of RA patients discontinue therapy within the first year of treatment

Pregnancy carried to childbirth increases risk of ACPA-negative RA

Pregnancy carried to childbirth increases risk of ACPA-negative RA

Study: Depression indicators are stronger predictors of work disability in early arthritis

Study: Depression indicators are stronger predictors of work disability in early arthritis

University of Oxford researchers receive grant to study genes that contribute to ankylosing spondylitis

University of Oxford researchers receive grant to study genes that contribute to ankylosing spondylitis

Study on the development of internet-based physical activity intervention presented at EULAR 2013

Study on the development of internet-based physical activity intervention presented at EULAR 2013

New study shows treatment with brodalumab demonstrates clinical response in subjects with PsA

New study shows treatment with brodalumab demonstrates clinical response in subjects with PsA

Celgene announces positive results from first phase III study of apremilast in psoriatic arthritis

Celgene announces positive results from first phase III study of apremilast in psoriatic arthritis

Researchers to launch Phase II clinical trial to investigate potential new therapy for sickle cell anemia

Researchers to launch Phase II clinical trial to investigate potential new therapy for sickle cell anemia

Home treatment improves chronic constipation in children

Home treatment improves chronic constipation in children

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.